Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can an ancient herbal mix tame psoriasis flares?

NCT ID NCT05815797

Disease control Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This trial tests whether a traditional Chinese herbal formula called SDD can safely reduce the severity of plaque psoriasis, a common inflammatory skin condition. Adults with mild-to-moderate psoriasis will receive either SDD or a placebo daily for 12 weeks. Researchers will measure changes in skin plaques and overall disease severity using standard scoring tools.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a Chinese herbal formula called Shuiniujiao Dihuang Decoction with Variation (SDD)
What this could lead to
If effective, SDD could offer a lower-cost, lower-side-effect option for managing mild-to-moderate plaque psoriasis.
What could go wrong
This is a small, early-phase trial with only 58 participants. The herbal formula contains 23 ingredients, making it hard to pinpoint which components work, and results may not apply to more severe psoriasis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 58 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2024

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Mild to moderate chronic plaque psoriasis (PASI score 3 to 12). * Willingness to give informed consent. Exclusion Criteria: * Pustular or generalized erythrodermic psoriasis. * Psoriatic arthritis with syndrome of spleen-kidney yang deficiency according to Chinese medicine theory. * Systemic therapy for psoriasis 6 months prior to baseline. * Use topical medications for psoriasis 14 days prior to baseline such as retinoids, corticosteroids, vitamin D analogues, tazarotene and tacrolimus. * Has taken any antibiotics, probiotics and prebiotics 30 days prior to baseline. * UV light therapy 30 days prior to baseline. * Clinically significant laboratory abnormality in blood, liver or renal functions (≥1.5 times the upper limit of reference range). * History of allergy to Chinese herbs. * Known pregnant or lactation, or have a plan to conceive in 6 months. * Known active gastric or duodenal ulcer, or severe arrhythmia. * Unwillingness to comply with study protocol. * Any other condition that in the opinion of the investigators could disadvantage the subject.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psoriasis vulgaris are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psoriasis vulgaris

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hong Kong Institute of Integrative Medicine

    RECRUITING

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.